C/EBPα-mediated ACSL4-dependent ferroptosis exacerbates tubular injury in diabetic kidney disease

Area of Science:

• Nephrology
• Molecular Biology
• Diabetes Complications

Background:

• Diabetic kidney disease (DKD) is a major diabetes complication with limited treatments.
• Progressive renal function decline characterizes DKD.
• Identifying novel therapeutic targets is crucial for DKD management.

Purpose of the Study:

• To investigate the role of CCAAT/enhancer binding protein alpha (C/EBPα) in diabetic kidney disease pathogenesis.
• To elucidate the molecular mechanisms by which C/EBPα contributes to DKD.
• To evaluate the therapeutic potential of targeting the C/EBPα pathway in DKD.

Main Methods:

• Analysis of C/EBPα expression in renal biopsy samples from DKD patients.
• RNA sequencing and proteomics to identify C/EBPα-regulated pathways.
• In vitro and in vivo studies to assess the impact of C/EBPα on tubular injury and ferroptosis.
• Investigating the binding of C/EBPα to the transcription regulatory sequence (TRS) of ACSL4.

Main Results:

• C/EBPα expression is increased in patients with DKD.
• C/EBPα exacerbates tubular injury by promoting acyl-CoA synthetase long-chain family member 4 (ACSL4)-dependent ferroptosis.
• C/EBPα upregulates ACSL4 expression via binding to its TRS, leading to increased lipid peroxidation and ferroptosis.
• Inhibition or genetic ablation of C/EBPα attenuates ferroptosis and mitigates tubular injury in DKD models.

Conclusions:

• The C/EBPα-ACSL4-ferroptosis pathway is a key driver of tubular injury in DKD.
• Targeting C/EBPα or its downstream effectors represents a promising therapeutic strategy for DKD.
• This study provides novel insights into the molecular mechanisms underlying DKD progression.